Modelling NAFLD disease burden in four Asian regions—2019‐2030Chris Estes, Homie Razavi, Henry Lik‐Yuen Chan et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 174
Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysisWon‐Mook Choi, Young‐Suk Lim, Terry Cheuk‐Fung Yip et al.|Journal of Hepatology|2022Cited by 62
Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patientsWon‐Mook Choi, Young‐Suk Lim, Terry Cheuk‐Fung Yip et al.|Hepatology|2024Cited by 33
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patientsMatt Liu, Jia‐Horng Kao, Tai‐Chung Tseng et al.|Hepatology International|2021Cited by 33
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohortYao‐Chun Hsu, Mindie H. Nguyen, Dae Won Jun et al.|Hepatology International|2022Cited by 27